9. Clowes WA, Reidy MA, Clowes MM: Kinetics of cellular proliferation after arterial injury. I. Smooth muscle growth in the absence of endothelium. Lab Invest49:208-215, 1983.
10.
10. Clowes AW, Reidy MA, Clowes MM: Mechanisms of stenosis after arterial injury. Lab Invest49:208-215, 1983.
11.
11. Han DKM, Haudenschild CC, Hong MK, et al: Evidence for apoptosis in human atherogenesis and in a rat vascular injury model. Am J Path147:267-277, 1995.
12.
12. Jackson CL, Reidy MA: Basic fibroblast growth factor: Its role in the control of smooth muscle cell migration. Am J Pathol143:1024-1031, 1993.
13.
13. Reidy MA: Neointimal proliferation: The role of basic FGF on vascular smooth muscle cell proliferation. Thromb Haemost70:172-176, 1993.
14.
14. Fingerle J, Johnson R, Clowes AW, et al: Role of platelets in smooth muscle cell proliferation and migration after vascular injury in rat carotid artery. Proc Natl Acad Sci USA86:8412-8416, 1989.
15.
15. Friedman RJ, Stemerman MB, Wenz B, et al: The effect of thrombocytopenia on experimental atherosclerotic lesion formation in rabbits. Smooth muscle cell proliferation and re-endothelialization. J Clin Invest60:1191-1201,1977.
16.
16. Edelman ER, Karnovsky MJ: Contrasting effects of the intermittent and continuous administration of heparin in experimental restenosis. Circulation89:770-776, 1994.
17.
17. Farhy RD, Carreter OA, Ho K-L, et al: Role of kinins and nitric oxide in the effects of angiotensin converting enzyme inhibitors on neointima formation. Circ Res72:1202-1210, 1993.
18.
18. Clowes AW, Clowes MM, Au YPT, et al: Smooth muscle cells express urokinase during mitogenesis and tissue-type plasminogen activator during migration in injured rat carotid artery. Circ Res67:61-67, 1990.
19.
19. Ferns GA, Raines EW, Sprugel KH, et al: Inhibition of neointimal smooth muscle accumulation after angioplasty by an antibody to PDGF. Science253:1129-1132, 1992.
20.
20. Jawien A, Bowen-Pope DF, Linder V, et al: Plateletderived growth factor promotes smooth muscle cell migration and intimal thickening in a rat model of balloon angioplasty. J Clin Invest89:507-511, 1992.
21.
21. Majesky MW, Lindner V, Twardzik DR, et al: Production of transforming growth factor beta during repair of arterial injury. J Clin Invest88:904-910, 1991.
22.
22. Cercek B, Fishbein MC, Forrester JS, et al: Induction of insulin-like growth factor I messenger RNA in rat aorta after balloon denudation. Circ Res66:1755-1760, 1990.
23.
23. Hansson GK, Jonasson L, Holm J, et al: Gamma interferon regulates vascular smooth muscle proliferation and la expression in vitro and in vivo. Circ Res63:712-719, 1988.
24.
24. Loppnow H, Libby P: Functional significance of human vascular smooth muscle cell-derived interleukin 1 in paracrine and autocrine regulation pathways. Cell Res198:283-290, 1992.
25.
25. Herrmann HC, Shunichiro O, Hozakowska E, et al: Inhibition of smooth muscle cell proliferation and experimental angioplasty. Restenosis by f-cyclodextrin tetradecasulfate. Arterioscler Thromb13:924-931, 1993.
26.
26. Faggiotto A, Ross R, Harker L: Studies of hypercholesterolemia in the nonhuman primate. Arteriosclerosis4:323-323, 1994.
27.
27. Snow AD, Bolender PP, Wight TN, et al: Heparin modulates the composition of the extracellular matrix domain surrounding arterial smooth muscle cells. Am J Pathol137:313-330, 1990.
28.
28. Kohler TR, Jawien A: Flow affects development of intimal hyperplasia after arterial injury in rats. Arterioscler Thromb12:963-971, 1992.
29.
29. Sumpio BE, Banes AJ: Response of porcine aortic smooth muscle cells to cyclic tensional deformation in culture. J Surg Res44:696-701, 1988.
30.
30. Powell JS, Clozel JP, Muller RKM, et al: Inhibitors of angiotensin-converting enzyme prevent myointimal proliferation after vascular injury. Science245:186-188, 1989.
31.
31. Clowes AW, Karnovsky MJ: Suppression by heparin of smooth muscle cell proliferation in injured arteries. Nature265:625-626, 1977.
32.
32. Huber KC, Schwartz RS, Edwards WD, et al: Effects of angiotensin converting enzyme inhibition on neointimal proliferation in a porcine coronary injury model. Am Heart J125:695-701, 1993.
33.
33. Churchill DA, Siegel CO, Minor ST, et al: Enalapril in the prevention of restenosis following intracoronary intervention in a swine model. Coronary Artery Dis4:461-467, 1993.
34.
34. Hanson SR, Powell JS, Dodson T, et al: Effects of angiotensin converting enzyme inhibition with cilazapril on intimal hyperplasia in injured arteries and vascular grafts in the baboon. Hypertension18:70-76, 1991.
35.
35. Heyndrickz GR, MERCATOR Study Group: Angiotensin-converting enzyme inhibitor in a human model of restenosis. Basic Res Cardiol88:169-182, 1993.
36.
36. MERCATOR Study Group: Does the new angiotensin converting enzyme inhibitor cilazapril prevent restenosis after percutaneous transluminal coronary angioplasty? Results of the MERCATOR study: A multicenter, randomized, double-blind, placebo-controlled trial. Circulation86:100-110, 1992.
37.
37. Ellis SG, Roubin GS, Wilentz J, et al: Effect of 18 to 24 hour heparin administration for prevention of restenosis after uncomplicated coronary angioplasty. Am Heart J117:777-782, 1989.
38.
38. Edelman ER, Adams DH, Karnovsky MS: Effect of controlled adventitial heparin delivery on smooth muscle cell proliferation following endothelial injury. PNAS87:3773-3777, 1990.
39.
39. Bachinsky WB, Barnathan ES, Liu H, et al: Sustained inhibition of intimal thickening: In vitro and in vivo effects of polymeric beta-cyclodextrin sulfate. J Clin Invest96:2583-2592, 1995.
40.
40. Simons M, Edelman ER, DeKeyser JL, et al: Antisense c-myb oligonucleotides inhibit intimal arterial smooth muscle cell accumulation in vivo. Nature359:67-70, 1992.
41.
41. Morishita R, Gibbons GH, Ellison KE, et al: Single intraluminal delivery of antisense cdc2 kinase and proliferating-cell nuclear antigen oligonucleotides results in chronic inhibition of neointimal hyperplasia. Proc Natl Acad Sci USA90:8474-8478, 1993.
42.
42. Chang MW, Barr E, Seltzer J, et al: Cytostatic gene therapy for vascular proliferative disorders with a constitutively active form of the retinoblastoma gene product. Science267:518-522, 1995.
43.
43. Waksman R, Robinson KA, Crocker IR, et al: Intracoronary low-dose beta-irradiation inhibits neointima formation after coronary artery balloon injury in the swine restenosis model. Circulation92:3025-3031, 1992.
44.
44. Eton D, Ahn SS: Photodynamic Therapy of Intimal Hyperplasia. Pharmacologic Suppression of Intimal Hyperplasia. Austin and Georgetown: RG Landes Co, 1993.
45.
45. Ohno T, Gordon D, San H, et al: Gene therapy for vascular smooth muscle cell proliferation after arterial injury. Science265:781-784, 1994.
46.
46. Lee SW, Trapnell BC, Rade JJ, et al: In vivo adenoviral vector-mediated gene transfer into balloon injured rat carotid arteries. Circ Res73:797-807, 1993.
47.
47. Lemarchand P, Jones M, Yamada I, et al: In vivo gene transfer and expression in normal uninjured blood vessels using replication-deficient recombinant adenovirus vectors. Circ Res72:1132-1138, 1993.
48.
48. Lynch CM, Clowes MM, Osborne WRA, et al: Longterm expression of human adenosine deaminase in vascular smooth muscle cells of rats: A model for gene therapy. Proc Natl Acad Sci89:1138-1142, 1992.